Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis.

Farrant M, Easton JD, Adelman EE, Cucchiara BL, Barsan WG, Tillman HJ, Elm JJ, Kim AS, Lindblad AS, Palesch YY, Zhao W, Pauls K, Walsh KB, Martí-Fàbregas J, Bernstein RA, Johnston SC.

JAMA Netw Open. 2019 Sep 4;2(9):e1910769. doi: 10.1001/jamanetworkopen.2019.10769.

2.

Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a preplanned pooled analysis of individual participant data.

Moullaali TJ, Wang X, Martin RH, Shipes VB, Robinson TG, Chalmers J, Suarez JI, Qureshi AI, Palesch YY, Anderson CS.

Lancet Neurol. 2019 Sep;18(9):857-864. doi: 10.1016/S1474-4422(19)30196-6.

PMID:
31397290
3.

Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke.

Johnston SC, Elm JJ, Easton JD, Farrant M, Barsan WG, Kim AS, Lindblad AS, Palesch YY, Zurita KG, Albers GW, Cucchiara BL, Kleindorfer DO, Lutsep HL, Pearson C, Sethi P, Vora N; POINT and Neurological Emergencies Treatment Trials Network Investigators.

Circulation. 2019 Aug 20;140(8):658-664. doi: 10.1161/CIRCULATIONAHA.119.040713. Epub 2019 Jun 26.

PMID:
31238700
4.

Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial.

Tillman H, Johnston SC, Farrant M, Barsan W, Elm JJ, Kim AS, Lindblad AS, Palesch YY, Easton JD.

JAMA Neurol. 2019 Jul 1;76(7):774-782. doi: 10.1001/jamaneurol.2019.0932.

PMID:
31034032
5.

Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial.

Selim M, Foster LD, Moy CS, Xi G, Hill MD, Morgenstern LB, Greenberg SM, James ML, Singh V, Clark WM, Norton C, Palesch YY, Yeatts SD; i-DEF Investigators.

Lancet Neurol. 2019 May;18(5):428-438. doi: 10.1016/S1474-4422(19)30069-9. Epub 2019 Mar 18.

PMID:
30898550
6.

Association of Very Early Serum Levels of S100B, Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and Spectrin Breakdown Product with Outcome in ProTECT III.

Frankel M, Fan L, Yeatts SD, Jeromin A, Vos PE, Wagner AK, Wolf BJ, Pauls Q, Lunney M, Merck LH, Hall CL, Palesch YY, Silbergleit R, Wright DW.

J Neurotrauma. 2019 Oct 15;36(20):2863-2871. doi: 10.1089/neu.2018.5809. Epub 2019 Jul 9.

PMID:
30794101
7.

The Effect of Goal-Directed Therapy on Patient Morbidity and Mortality After Traumatic Brain Injury: Results From the Progesterone for the Treatment of Traumatic Brain Injury III Clinical Trial.

Merck LH, Yeatts SD, Silbergleit R, Manley GT, Pauls Q, Palesch Y, Conwit R, Le Roux P, Miller J, Frankel M, Wright DW.

Crit Care Med. 2019 May;47(5):623-631. doi: 10.1097/CCM.0000000000003680.

PMID:
30730438
8.

Clinical Outcomes Depending on Acute Blood Pressure After Cerebral Hemorrhage.

Toyoda K, Koga M, Yamamoto H, Foster L, Palesch YY, Wang Y, Sakai N, Hara T, Hsu CY, Itabashi R, Sato S, Fukuda-Doi M, Steiner T, Yoon BW, Hanley DF, Qureshi AI; ATACH-2 Trial Investigators.

Ann Neurol. 2019 Jan;85(1):105-113. doi: 10.1002/ana.25379. Epub 2019 Jan 7.

PMID:
30421455
9.

Statistical analysis plan for pooled individual patient data from two landmark randomized trials (INTERACT2 and ATACH-II) of intensive blood pressure lowering treatment in acute intracerebral hemorrhage.

Moullaali TJ, Wang X, Martin RH, Shipes VB, Qureshi AI, Anderson CS, Palesch YY.

Int J Stroke. 2019 Apr;14(3):321-328. doi: 10.1177/1747493018813695. Epub 2018 Nov 12.

PMID:
30418098
10.

The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: Rationale and methods.

Kamel H, Longstreth WT Jr, Tirschwell DL, Kronmal RA, Broderick JP, Palesch YY, Meinzer C, Dillon C, Ewing I, Spilker JA, Di Tullio MR, Hod EA, Soliman EZ, Chaturvedi S, Moy CS, Janis S, Elkind MS.

Int J Stroke. 2019 Feb;14(2):207-214. doi: 10.1177/1747493018799981. Epub 2018 Sep 10.

11.

Treatment effect on ordinal functional outcome using piecewise multistate Markov model with unobservable baseline: an application to the modified Rankin scale.

Cassarly C, Martin RH, Chimowitz M, Peña EA, Ramakrishnan V, Palesch YY.

J Biopharm Stat. 2019;29(1):82-97. doi: 10.1080/10543406.2018.1489404. Epub 2018 Jul 9.

PMID:
29985739
12.

Blood Pressure-Attained Analysis of ATACH 2 Trial.

Qureshi AI, Palesch YY, Foster LD, Barsan WG, Goldstein JN, Hanley DF, Hsu CY, Moy CS, Qureshi MH, Silbergleit R, Suarez JI, Toyoda K, Yamamoto H; ATACH 2 Trial Investigators.

Stroke. 2018 Jun;49(6):1412-1418. doi: 10.1161/STROKEAHA.117.019845. Epub 2018 May 22.

PMID:
29789395
13.

Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.

Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators.

N Engl J Med. 2018 Jul 19;379(3):215-225. doi: 10.1056/NEJMoa1800410. Epub 2018 May 16.

14.

Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging.

Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, McTaggart RA, Torbey MT, Kim-Tenser M, Leslie-Mazwi T, Sarraj A, Kasner SE, Ansari SA, Yeatts SD, Hamilton S, Mlynash M, Heit JJ, Zaharchuk G, Kim S, Carrozzella J, Palesch YY, Demchuk AM, Bammer R, Lavori PW, Broderick JP, Lansberg MG; DEFUSE 3 Investigators.

N Engl J Med. 2018 Feb 22;378(8):708-718. doi: 10.1056/NEJMoa1713973. Epub 2018 Jan 24.

15.

Reply to: Prehospital Intubation: Further Confounders in Trial Results.

Nuño T, Denninghoff KR, Pauls Q, Yeatts SD, Silbergleit R, Palesch YY, Merck LH, Manley G, Wright DW.

Prehosp Emerg Care. 2018 Jul-Aug;22(4):537. doi: 10.1080/10903127.2017.1408729. Epub 2018 Jan 17. No abstract available.

PMID:
29338483
16.

Assessing type I error and power of multistate Markov models for panel data-A simulation study.

Cassarly C, Martin RH, Chimowitz M, Peña EA, Ramakrishnan V, Palesch YY.

Commun Stat Simul Comput. 2017;46(9):7040-7061. doi: 10.1080/03610918.2016.1222425. Epub 2016 Sep 23.

17.

Comparison of multistate Markov modeling with contemporary outcomes in a reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.

Cassarly C, Martin RH, Chimowitz M, Peña EA, Ramakrishnan V, Palesch YY.

PLoS One. 2017 Oct 26;12(10):e0187050. doi: 10.1371/journal.pone.0187050. eCollection 2017.

18.

A multicenter randomized controlled trial of endovascular therapy following imaging evaluation for ischemic stroke (DEFUSE 3).

Albers GW, Lansberg MG, Kemp S, Tsai JP, Lavori P, Christensen S, Mlynash M, Kim S, Hamilton S, Yeatts SD, Palesch Y, Bammer R, Broderick J, Marks MP.

Int J Stroke. 2017 Oct;12(8):896-905. doi: 10.1177/1747493017701147. Epub 2017 Mar 24.

19.

Endovascular Therapy Demonstrates Benefit over Intravenous Recombinant Tissue Plasminogen Activator Based on Repeatedly Measured National Institutes of Health Stroke Scale.

Fan L, Yeatts SD, Foster LD, Khatri P, Tomsick T, Broderick JP, Palesch YY.

Interv Neurol. 2017 Mar;6(1-2):25-30. doi: 10.1159/000452137. Epub 2016 Oct 19.

20.

Prehospital Intubation is Associated with Favorable Outcomes and Lower Mortality in ProTECT III.

Denninghoff KR, Nuño T, Pauls Q, Yeatts SD, Silbergleit R, Palesch YY, Merck LH, Manley GT, Wright DW.

Prehosp Emerg Care. 2017 Sep-Oct;21(5):539-544. doi: 10.1080/10903127.2017.1315201. Epub 2017 May 10.

PMID:
28489506
21.

Observed Cost and Variations in Short Term Cost-Effectiveness of Therapy for Ischemic Stroke in Interventional Management of Stroke (IMS) III.

Simpson KN, Simpson AN, Mauldin PD, Palesch YY, Yeatts SD, Kleindorfer D, Tomsick TA, Foster LD, Demchuk AM, Khatri P, Hill MD, Jauch EC, Jovin TG, Yan B, von Kummer R, Molina CA, Goyal M, Schonewille WJ, Mazighi M, Engelter ST, Anderson C, Spilker J, Carrozzella J, Ryckborst KJ, Janis LS, Broderick JP; Interventional Management of Stroke (IMS) III Investigators.

J Am Heart Assoc. 2017 May 8;6(5). pii: e004513. doi: 10.1161/JAHA.116.004513.

22.

Stroke Recovery and Rehabilitation Research: Issues, Opportunities, and the National Institutes of Health StrokeNet.

Cramer SC, Wolf SL, Adams HP Jr, Chen D, Dromerick AW, Dunning K, Ellerbe C, Grande A, Janis S, Lansberg MG, Lazar RM, Palesch YY, Richards L, Roth E, Savitz SI, Wechsler LR, Wintermark M, Broderick JP.

Stroke. 2017 Mar;48(3):813-819. doi: 10.1161/STROKEAHA.116.015501. Epub 2017 Feb 7. No abstract available.

23.

Intensive Blood-Pressure Lowering in Cerebral Hemorrhage.

Qureshi AI, Palesch YY, Suarez JI.

N Engl J Med. 2016 Dec 8;375(23):e48. doi: 10.1056/NEJMc1613117. No abstract available.

PMID:
27959682
24.

Power of an Adaptive Trial Design for Endovascular Stroke Studies: Simulations Using IMS (Interventional Management of Stroke) III Data.

Lansberg MG, Bhat NS, Yeatts SD, Palesch YY, Broderick JP, Albers GW, Lai TL, Lavori PW.

Stroke. 2016 Dec;47(12):2931-2937. Epub 2016 Nov 15.

25.

Endovascular Therapy of M2 Occlusion in IMS III: Role of M2 Segment Definition and Location on Clinical and Revascularization Outcomes.

Tomsick TA, Carrozzella J, Foster L, Hill MD, von Kummer R, Goyal M, Demchuk AM, Khatri P, Palesch Y, Broderick JP, Yeatts SD, Liebeskind DS; IMS III Investigators.

AJNR Am J Neuroradiol. 2017 Jan;38(1):84-89. doi: 10.3174/ajnr.A4979. Epub 2016 Oct 20.

26.

ALIAS (Albumin in Acute Ischemic Stroke) Trials: Analysis of the Combined Data From Parts 1 and 2.

Martin RH, Yeatts SD, Hill MD, Moy CS, Ginsberg MD, Palesch YY; ALIAS Parts 1 and 2 and NETT Investigators.

Stroke. 2016 Sep;47(9):2355-9. doi: 10.1161/STROKEAHA.116.012825. Epub 2016 Jul 26.

27.

Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage.

Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, Moy CS, Silbergleit R, Steiner T, Suarez JI, Toyoda K, Wang Y, Yamamoto H, Yoon BW; ATACH-2 Trial Investigators and the Neurological Emergency Treatment Trials Network.

N Engl J Med. 2016 Sep 15;375(11):1033-43. doi: 10.1056/NEJMoa1603460. Epub 2016 Jun 8.

28.

Very Early Administration of Progesterone Does Not Improve Neuropsychological Outcomes in Subjects with Moderate to Severe Traumatic Brain Injury.

Goldstein FC, Caveney AF, Hertzberg VS, Silbergleit R, Yeatts SD, Palesch YY, Levin HS, Wright DW.

J Neurotrauma. 2017 Jan 1;34(1):115-120. doi: 10.1089/neu.2015.4313. Epub 2016 Apr 15.

29.

Effect of endovascular reperfusion in relation to site of arterial occlusion.

Lemmens R, Hamilton SA, Liebeskind DS, Tomsick TA, Demchuk AM, Nogueira RG, Marks MP, Jahan R, Gralla J, Yoo AJ, Yeatts SD, Palesch YY, Saver JL, Pereira VM, Broderick JP, Albers GW, Lansberg MG; DEFUSE 2, IMS III, STAR, and SWIFT trialists; DEFUSE 2 IMS III STAR and SWIFT trialists.

Neurology. 2016 Feb 23;86(8):762-70. doi: 10.1212/WNL.0000000000002399. Epub 2016 Jan 22.

30.

The National Institutes of Health StrokeNet: A User's Guide.

Broderick JP, Palesch YY, Janis LS; National Institutes of Health StrokeNet Investigators.

Stroke. 2016 Feb;47(2):301-3. doi: 10.1161/STROKEAHA.115.011743. Epub 2015 Dec 29. No abstract available.

31.

Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.

Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy EI, Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE; American Heart Association Stroke Council and Council on Epidemiology and Prevention.

Stroke. 2016 Feb;47(2):581-641. doi: 10.1161/STR.0000000000000086. Epub 2015 Dec 22. Review. Erratum in: Stroke. 2016 Nov;47(11):e262.

PMID:
26696642
32.

The impact of covariate misclassification using generalized linear regression under covariate-adaptive randomization.

Fan L, Yeatts SD, Wolf BJ, McClure LA, Selim M, Palesch YY.

Stat Methods Med Res. 2018 Jan;27(1):20-34. doi: 10.1177/0962280215616405. Epub 2015 Nov 23.

33.

Endovascular Therapy Is Effective and Safe for Patients With Severe Ischemic Stroke: Pooled Analysis of Interventional Management of Stroke III and Multicenter Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke in the Netherlands Data.

Broderick JP, Berkhemer OA, Palesch YY, Dippel DW, Foster LD, Roos YB, van der Lugt A, Tomsick TA, Majoie CB, van Zwam WH, Demchuk AM, van Oostenbrugge RJ, Khatri P, Lingsma HF, Hill MD, Roozenbeek B, Jauch EC, Jovin TG, Yan B, von Kummer R, Molina CA, Goyal M, Schonewille WJ, Mazighi M, Engelter ST, Anderson CS, Spilker J, Carrozzella J, Ryckborst KJ, Janis LS, Simpson KN; IMS III Investigators; MR CLEAN Investigators.

Stroke. 2015 Dec;46(12):3416-22. doi: 10.1161/STROKEAHA.115.011397. Epub 2015 Oct 20. Erratum in: Stroke. 2016 Jan;47(1):e21. IMS II [corrected to IMS III Investigators].

34.

Albumin Administration in Acute Ischemic Stroke: Safety Analysis of the ALIAS Part 2 Multicenter Trial.

Hill MD, Martin RH, Palesch YY, Moy CS, Tamariz D, Ryckborst KJ, Jones EB, Weisman D, Pettigrew C, Ginsberg MD.

PLoS One. 2015 Sep 1;10(9):e0131390. doi: 10.1371/journal.pone.0131390. eCollection 2015.

35.

Outcome Differences between Intra-Arterial Iso- and Low-Osmolality Iodinated Radiographic Contrast Media in the Interventional Management of Stroke III Trial.

Tomsick TA, Foster LD, Liebeskind DS, Hill MD, Carrozella J, Goyal M, von Kummer R, Demchuk AM, Dzialowski I, Puetz V, Jovin T, Morales H, Palesch YY, Broderick J, Khatri P, Yeatts SD; IMS III Investigators.

AJNR Am J Neuroradiol. 2015 Nov;36(11):2074-81. doi: 10.3174/ajnr.A4421. Epub 2015 Jul 30.

36.

Imaging in StrokeNet: Realizing the Potential of Big Data.

Liebeskind DS, Albers GW, Crawford K, Derdeyn CP, George MS, Palesch YY, Toga AW, Warach S, Zhao W, Brott TG, Sacco RL, Khatri P, Saver JL, Cramer SC, Wolf SL, Broderick JP, Wintermark M.

Stroke. 2015 Jul;46(7):2000-6. doi: 10.1161/STROKEAHA.115.009479. Epub 2015 Jun 4. Review. No abstract available.

37.

Assessing the impact of safety monitoring on the efficacy analysis in large Phase III group sequential trials with non-trivial safety event rate.

Weng Y, Palesch YY, DeSantis SM, Zhao W.

J Biopharm Stat. 2016;26(4):672-85. doi: 10.1080/10543406.2015.1052473. Epub 2015 May 26.

38.

Twelve-Month Clinical and Quality-of-Life Outcomes in the Interventional Management of Stroke III Trial.

Palesch YY, Yeatts SD, Tomsick TA, Foster LD, Demchuk AM, Khatri P, Hill MD, Jauch EC, Jovin TG, Yan B, von Kummer R, Molina CA, Goyal M, Schonewille WJ, Mazighi M, Engelter ST, Anderson C, Spilker J, Carrozzella J, Ryckborst KJ, Janis LS, Simpson A, Simpson KN, Broderick JP; Interventional Management of Stroke III Investigators.

Stroke. 2015 May;46(5):1321-7. doi: 10.1161/STROKEAHA.115.009180. Epub 2015 Apr 9.

39.

Multi-modality neuro-monitoring: conventional clinical trial design.

Georgiadis AL, Palesch YY, Zygun D, Hemphill JC 3rd, Robertson CS, Leroux PD, Suarez JI; Second Neurocritical Care Research Conference Investigators.

Neurocrit Care. 2015 Jun;22(3):369-77. doi: 10.1007/s12028-015-0134-9. Review.

PMID:
25832350
40.

A surrogate-primary replacement algorithm for response-adaptive randomization in stroke clinical trials.

Nowacki AS, Zhao W, Palesch YY.

Stat Methods Med Res. 2017 Jun;26(3):1078-1092. doi: 10.1177/0962280214567142. Epub 2015 Jan 12.

41.

Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis.

Adeoye O, Sucharew H, Khoury J, Tomsick T, Khatri P, Palesch Y, Schmit PA, Pancioli AM, Broderick JP; CLEAR-ER, IMS III, and ALIAS Part 2 Investigators.

Stroke. 2015 Feb;46(2):461-4. doi: 10.1161/STROKEAHA.114.006743. Epub 2014 Dec 18.

42.

Very early administration of progesterone for acute traumatic brain injury.

Wright DW, Yeatts SD, Silbergleit R, Palesch YY, Hertzberg VS, Frankel M, Goldstein FC, Caveney AF, Howlett-Smith H, Bengelink EM, Manley GT, Merck LH, Janis LS, Barsan WG; NETT Investigators.

N Engl J Med. 2014 Dec 25;371(26):2457-66. doi: 10.1056/NEJMoa1404304. Epub 2014 Dec 10.

43.

Some common misperceptions about P values.

Palesch YY.

Stroke. 2014 Dec;45(12):e244-6. doi: 10.1161/STROKEAHA.114.006138. Epub 2014 Nov 6. Review. No abstract available.

44.

Endovascular revascularization results in IMS III: intracranial ICA and M1 occlusions.

Tomsick TA, Yeatts SD, Liebeskind DS, Carrozzella J, Foster L, Goyal M, von Kummer R, Hill MD, Demchuk AM, Jovin T, Yan B, Zaidat OO, Schonewille W, Engelter S, Martin R, Khatri P, Spilker J, Palesch YY, Broderick JP; IMS III Investigators.

J Neurointerv Surg. 2015 Nov;7(11):795-802. doi: 10.1136/neurintsurg-2014-011318. Epub 2014 Oct 23.

PMID:
25342652
45.

Evolution of practice during the Interventional Management of Stroke III Trial and implications for ongoing trials.

Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, Jauch EC, Jovin TG, Yan B, von Kummer R, Molina CA, Goyal M, Mazighi M, Schonewille WJ, Engelter ST, Anderson C, Spilker J, Carrozzella J, Janis LS, Foster LD, Tomsick TA; Interventional Management of Stroke III Investigators.

Stroke. 2014 Dec;45(12):3606-11. doi: 10.1161/STROKEAHA.114.005952. Epub 2014 Oct 16.

46.

Interpretation and Implementation of Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT II).

Qureshi AI, Palesch YY, Martin R, Toyoda K, Yamamoto H, Wang Y, Wang Y, Hsu CY, Yoon BW, Steiner T, Butcher K, Hanley DF, Suarez JI.

J Vasc Interv Neurol. 2014 Jun;7(2):34-40. No abstract available.

47.

Screen failure data in clinical trials: Are screening logs worth it?

Elm JJ, Palesch Y, Easton JD, Lindblad A, Barsan W, Silbergleit R, Conwit R, Dillon C, Farrant M, Battenhouse H, Perlmutter A, Johnston SC.

Clin Trials. 2014 Aug;11(4):467-472. Epub 2014 Jun 12.

48.

Recanalization and clinical outcome of occlusion sites at baseline CT angiography in the Interventional Management of Stroke III trial.

Demchuk AM, Goyal M, Yeatts SD, Carrozzella J, Foster LD, Qazi E, Hill MD, Jovin TG, Ribo M, Yan B, Zaidat OO, Frei D, von Kummer R, Cockroft KM, Khatri P, Liebeskind DS, Tomsick TA, Palesch YY, Broderick JP; IMS III Investigators.

Radiology. 2014 Oct;273(1):202-10. doi: 10.1148/radiol.14132649. Epub 2014 Jun 5.

49.

Drivers of costs associated with reperfusion therapy in acute stroke: the Interventional Management of Stroke III Trial.

Simpson KN, Simpson AN, Mauldin PD, Hill MD, Yeatts SD, Spilker JA, Foster LD, Khatri P, Martin R, Jauch EC, Kleindorfer D, Palesch YY, Broderick JP; IMS III Investigators.

Stroke. 2014 Jun;45(6):1791-8. doi: 10.1161/STROKEAHA.113.003874. Epub 2014 May 13.

50.

Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial.

Khatri P, Yeatts SD, Mazighi M, Broderick JP, Liebeskind DS, Demchuk AM, Amarenco P, Carrozzella J, Spilker J, Foster LD, Goyal M, Hill MD, Palesch YY, Jauch EC, Haley EC, Vagal A, Tomsick TA; IMS III Trialists.

Lancet Neurol. 2014 Jun;13(6):567-74. doi: 10.1016/S1474-4422(14)70066-3. Epub 2014 Apr 27.

Supplemental Content

Loading ...
Support Center